Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
First-in-human single ascending dose study of GAL-475 in healthy men and men with sleep apnea
NL-OMON55229Phase 1Active, not recruiting
- Sponsor
- Neurim Pharmaceuticals
- Start
- Jan 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1, randomised, double-blind trial in central sleep apnea (CSA), obstructive sleep apnea hypopnea syndrome (OSAHS), mixed sleep apnea (MA) and 1 more comparing GAL-475 with Placebo (2 arms). Primary endpoints: Safety and tolerability in healthy subjects, Pharmacokinetics in healthy subjects and 1 more. Started Jan 2021; status: active, not recruiting.
02
Drugs
GAL-475
03
Conditions
central sleep apnea (CSA)obstructive sleep apnea hypopnea syndrome (OSAHS)mixed sleep apnea (MA)sleep disordered breathing (SDB)
Beyond the preview
Go deeper on NL-OMON55229.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON55229.